Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 9381513, 8 pages
https://doi.org/10.1155/2017/9381513
Research Article

Therapy Effects of Wogonin on Ovarian Cancer Cells

1Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China
2College of Life Science, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China
3Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology, Hangzhou, Zhejiang 310022, China

Correspondence should be addressed to Gu Linhui; ten.haey@ugiuhnil

Received 24 June 2017; Revised 23 August 2017; Accepted 10 September 2017; Published 18 October 2017

Academic Editor: Gang Liu

Copyright © 2017 Jiang Ruibin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Chen, M. Cooper, M. Jones et al., “Combined activity of oridonin and wogonin in advanced-stage ovarian cancer cells,” Cell Biology and Toxicology, vol. 27, no. 2, pp. 133–147, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Spiliotis, E. Halkia, E. Lianos et al., “Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study,” Annals of Surgical Oncology, vol. 22, no. 5, pp. 1570–1575, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. A. L. Shafrir, M. S. Rice, M. Gupta et al., “The association between reproductive and hormonal factors and ovarian cancer by estrogen-α and progesterone receptor status,” Gynecologic Oncology, vol. 143, no. 3, pp. 628–635, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Dudko, T. Bogush, S. Kolomiytsev et al., “Quantitative analysis of estrogen receptors alpha and beta expression in ovarian cancer patients by flow cytometry,” European Journal of Cancer, vol. 61, p. S71, 2016. View at Publisher · View at Google Scholar
  5. M. van Kruchten, E. F. J. de Vries, H. J. G. Arts et al., “Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT,” Journal of Nuclear Medicine, vol. 56, no. 1, pp. 50–55, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. M.-A. Park, K.-A. Hwang, H.-R. Lee, B.-R. Yi, E.-B. Jeung, and K.-C. Choi, “Benzophenone-1 stimulated the growth of BG-1 ovarian cancer cells by cell cycle regulation via an estrogen receptor alpha-mediated signaling pathway in cellular and xenograft mouse models,” Toxicology, vol. 305, pp. 41–48, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Lu, Y. Xu, X. Wei, Z. Zhao, J. Xue, and P. Liu, “Emodin inhibits the epithelial to mesenchymal transition of epithelial ovarian cancer cells via ILK/GSK-3β/Slug signaling pathway,” BioMed Research International, vol. 2016, Article ID 6253280, 16 pages, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. K. K.-L. Chan, T. H.-Y. Leung, D. W. Chan et al., “Targeting estrogen receptor subtypes (ERα and ERβ) with selective ER modulators in ovarian cancer,” Journal of Endocrinology, vol. 221, no. 2, pp. 325–336, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Fujimoto, R. Hirose, H. Sakaguchi, and T. Tamaya, “Clinical significance of expression of estrogen receptor α and β mRMAs in ovarian cancers,” Oncology, vol. 58, no. 4, pp. 334–341, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Li, Q. Zhuang, X. Lan, G. Zeng, X. Jiang, and Z. Huang, “PES1 differentially regulates the expression of ERα and ERβ in ovarian cancer,” IUBMB Life, vol. 65, no. 12, pp. 1017–1025, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. C.-H. Chien, F.-F. Wang, and T. C. Hamilton, “Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells,” Molecular and Cellular Endocrinology, vol. 99, no. 1, pp. 11–19, 1994. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Galtier, J. M. Nores, and J. M. Remy, “Beta blockade prophylaxis of accessory pathway catecholamine sensitive circus movement tachycardia,” The European journal of medicine, vol. 1, no. 2, pp. 125-126, 1992. View at Google Scholar · View at Scopus
  13. J.-H. Choi, K.-T. Lee, and P. C. K. Leung, “Estrogen receptor alpha pathway is involved in leptin-induced ovarian cancer cell growth,” Carcinogenesis, vol. 32, no. 4, pp. 589–596, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Scafonas, A. A. Reszka, D. B. Kimmel et al., “Agonist-like SERM effects on ERα-mediated repression of MMP1 promoter activity predict in vivo effects on bone and uterus,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 110, no. 3-5, pp. 197–206, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. Sharma SFCMWTSYA, “Determining the role of somatic ERα mutations in acquired hormone (or SERM) resistance,” Cancer Research, vol. 75, no. 9, article 4, 2015. View at Google Scholar
  16. K. Ohta, T. Ogawa, A. Kaise, and Y. Endo, “Synthesis and biological evaluation of novel m-carborane-containing estrogen receptor partial agonists as SERM candidates,” Bioorganic and Medicinal Chemistry Letters, vol. 25, no. 16, pp. 3213–3216, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. J. I. Dower, J. M. Geleijnse, L. Gijsbers, P. L. Zock, D. Kromhout, and P. C. H. Hollman, “Effects of the pure flavonoids epicatechin and quercetin on vascular function and cardiometabolic health: a randomized, double-blind, placebo-controlled, crossover trial,” American Journal of Clinical Nutrition, vol. 101, no. 5, pp. 914–921, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. S. D. S. Banjarnahor and N. Artanti, “Antioxidant properties of flavonoids,” Medical Journal of Indonesia, vol. 23, no. 4, pp. 239–244, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. X. Shi, D. Liu, J. Zhang et al., “Extraction and purification of total flavonoids from pine needles of Cedrus deodara contribute to anti-tumor in vitro,” BMC Complementary and Alternative Medicine, vol. 16, article no. 245, 2016. View at Publisher · View at Google Scholar
  20. L.-G. Chen, L.-Y. Hung, K.-W. Tsai et al., “Wogonin, a bioactive flavonoid in herbal tea, inhibits inflammatory cyclooxygenase-2 gene expression in human lung epithelial cancer cells,” Molecular Nutrition and Food Research, vol. 52, no. 11, pp. 1349–1357, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Chen, L. Zhang, G. Yan et al., “Neutrophil-to-lymphocyte ratio is a potential prognostic biomarker in patients with ovarian cancer: a meta-analysis,” BioMed Research International, vol. 2017, pp. 1–7, 2017. View at Publisher · View at Google Scholar
  22. F. Chen, R. Wu, Z. Zhu et al., “Wogonin protects rat dorsal root ganglion neurons against tunicamycin-induced ER stress through the PERK-eIF2α-ATF4 signaling pathway,” Journal of Molecular Neuroscience, vol. 55, no. 4, pp. 995–1005, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Wozniak, A. Drys, and A. Matkowski, “Antiradical and antioxidant activity of flavones from Scutellariae baicalensis radix,” Natural Product Research, vol. 29, no. 16, pp. 1567–1570, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. D.-H. Lee, C. Kim, L. Zhang, and Y. J. Lee, “Role of p53, PUMA, and Bax in wogonin-induced apoptosis in human cancer cells,” Biochemical Pharmacology, vol. 75, no. 10, pp. 2020–2033, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. D.-H. Lee, T. H. Lee, C. H. Jung, and Y.-H. Kim, “Wogonin induces apoptosis by activating the AMPK and p53 signaling pathways in human glioblastoma cells,” Cellular Signalling, vol. 24, no. 11, pp. 2216–2225, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Yang, H.-W. Zhang, R. Hu et al., “Wogonin induces G1 phase arrest through inhibiting Cdk4 and cyclin D1 concomitant with an elevation in p21Cip1 in human cervical carcinoma HeLa cells,” Biochemistry and Cell Biology, vol. 87, no. 6, pp. 933–942, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Lu, Y. Gao, Y. Ling et al., “Wogonin suppresses tumor growth in vivo and VEGF-induced angiogenesis through inhibiting tyrosine phosphorylation of VEGFR2,” Life Sciences, vol. 82, no. 17-18, pp. 956–963, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. X. Song, Y. Zhou, M. Zhou et al., “Wogonin influences vascular permeability via Wnt/β-catenin pathway,” Molecular Carcinogenesis, vol. 54, no. 7, pp. 501–512, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Q. Yu, H. B. Liu, D. Z. Tian, Y. W. Liu, J. C. Lei, and G. L. Zou, “Changes in mitochondrial membrane potential and reactive oxygen species during wogonin-induced cell death in human hepatoma cells,” Hepatology Research, vol. 37, no. 1, pp. 68–76, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Feng, S. Zhang, K. Wu et al., “Combined effects of suberoylanilide hydroxamic acid and cisplatin on radiation sensitivity and cancer cell invasion in non-small cell lung cancer,” Molecular Cancer Therapeutics, vol. 15, no. 5, pp. 842–853, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Liu, G. Guan, and J. Fang, “Macleaya cordata extract decreased diarrhea score and enhanced intestinal barrier function in growing piglets,” BioMed Research International, vol. 2016, Article ID 1069585, 7 pages, 2016. View at Publisher · View at Google Scholar
  32. G. Liu, S. Chen, J. Zhong, K. Teng, and Y. Yin, “Crosstalk between tryptophan metabolism and cardiovascular disease, mechanisms, and therapeutic implications,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 1602074, 5 pages, 2017. View at Publisher · View at Google Scholar
  33. W. L. W. Hsiao and L. Liu, “The role of traditional Chinese herbal medicines in cancer therapy—from TCM theory to mechanistic insights,” Planta Medica, vol. 76, no. 11, pp. 1118–1131, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Hu, M. Xu, R. Qin, W. Chen, and X. Xu, “Wogonin induces apoptosis and endoplasmic reticulum stress in HL-60 leukemia cells through inhibition of the PI3K-AKT signaling pathway,” Oncology Reports, vol. 33, no. 6, pp. 3146–3154, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. W. Wang, Q. Guo, Q. You et al., “Involvement of bax/bcl-2 in wogonin-induced apoptosis of human hepatoma cell line SMMC-7721,” Anti-Cancer Drugs, vol. 17, no. 7, pp. 797–805, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. K. F. Huang, G. D. Zhang, Y. Q. Huang, and Y. Diao, “Wogonin induces apoptosis and down-regulates survivin in human breast cancer MCF-7 cells by modulating PI3K-AKT pathway,” International Immunopharmacology, vol. 12, no. 2, pp. 334–341, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. S. H. Erdman, H. D. Wu, L. J. Hixson, D. J. Ahnen, and E. W. Gerner, “Assessment of mutations in Ki-ras and p53 in colon cancers from azoxymethane- and dimethylhydrazine-treated rats,” Molecular Carcinogenesis, vol. 19, no. 2, pp. 137–144, 1997. View at Publisher · View at Google Scholar · View at Scopus
  38. F. Kruiswijk, C. F. Labuschagne, and K. H. Vousden, “P53 in survival, death and metabolic health: a lifeguard with a licence to kill,” Nature Reviews Molecular Cell Biology, vol. 16, no. 7, pp. 393–405, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. V. Kirkin, S. Joos, and M. Zörnig, “The role of Bcl-2 family members in tumorigenesis,” Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, vol. 1644, no. 2-3, pp. 229–249, 2004. View at Publisher · View at Google Scholar
  40. M. K. Manion and D. M. Hockenbery, “Targeting BCL-2-related proteins in cancer therapy,” Cancer Biology & Therapy, vol. 2, supplement 1, no. 4, pp. S105–S114, 2003. View at Google Scholar · View at Scopus
  41. F. Acconcia, P. Totta, S. Ogawa et al., “Survival versus apoptotic 17β-estradiol effect: role of ERα and ERβ activated non-genomic signaling,” Journal of Cellular Physiology, vol. 203, no. 1, pp. 193–201, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Mauro, M. Pellegrino, F. Giordano et al., “Estrogen receptor-α drives adiponectin effects on cyclin D1 expression in breast cancer cells,” FASEB Journal, vol. 29, no. 5, pp. 2150–2160, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. E. Burandt, M. Grünert, A. Lebeau et al., “Cyclin D1 gene amplification is highly homogeneous in breast cancer,” Breast Cancer, vol. 23, no. 1, pp. 111–119, 2016. View at Publisher · View at Google Scholar · View at Scopus
  44. X. Li, X. Gong, J. Chen, J. Zhang, J. Sun, and M. Guo, “MiR-340 inhibits glioblastoma cell proliferation by suppressing CDK6, cyclin-D1 and cyclin-D2,” Biochemical and Biophysical Research Communications, vol. 460, no. 3, pp. 670–677, 2015. View at Publisher · View at Google Scholar · View at Scopus
  45. Y.-F. Tao, N.-N. Wang, L.-X. Xu et al., “Molecular mechanism of G1 arrest and cellular senescence induced by LEE011, a novel CDK4/CDK6 inhibitor, in leukemia cells,” Cancer Cell International, vol. 17, no. 1, article no. 35, 2017. View at Publisher · View at Google Scholar · View at Scopus